Liquidia Technologies
  |   |   |
   Home  |  Site Map  |  Contact Us  
  

Company

Overview
Management Team
Board of Directors
Investors
Partnerships
Contact

Management Team

Neal Fowler, Chief Executive Officer
Mr. Fowler joined Liquidia in 2008 after seven successful years at Johnson & Johnson (J&J). While at J&J, Neal served as President of Centocor, Inc., a multi-billion dollar subsidiary focused on development and commercialization of industry leading biomedicines used in the treatment of chronic inflammatory diseases. At Centocor, Mr. Fowler prepared the company for the launch of two potential blockbuster products and continued the company's legacy of double-digit growth for their flagship product REMICADE® (infliximab). Prior to Centocor, Mr. Fowler was president of Ortho-McNeil Neurologics Inc. and vice president of the central nervous system franchise at Ortho-McNeil Pharmaceuticals. Mr. Fowler joined J&J after a successful 13-year career at Eli Lilly and Company where he held a variety of sales, marketing and business development roles with increasing responsibilities in both the pharmaceutical and medical divisions. Mr. Fowler is a native of Raleigh, NC and received a Bachelor of Science degree in Pharmacy and Masters of Business Administration from the University of North Carolina at Chapel Hill (UNC-CH).

Tim Albury, Chief Financial Officer
Before joining Liquidia in 2013, Mr. Albury served as the Chief Financial Officer of Osmotica Pharmaceutical Corp., a multinational specialty pharmaceutical company and one of the world leaders in osmotic drug delivery with several products commercialized. Prior to that, Mr. Albury served as the Chief Financial Officer for KBI Biopharma, a world leader in contract biopharmaceutical drug development. Earlier in his career, Mr. Albury served as the Chief Financial Officer of Ardent Pharmaceuticals, a specialty pharmaceutical company focused on the development of a broad drug portfolio based upon delta receptor pharmacology. Prior to these industry roles, Mr. Albury served for 12 years in the Assurance & Business Advisory practice of Arthur Andersen, focused on the life sciences industry and healthcare. Mr. Albury is a Certified Public Accountant in North Carolina and Florida. He earned his master's degree in Professional Accountancy at the University of Miami.

Robert A. Lippe, Chief Operations Officer
Prior to joining Liquidia, Mr. Lippe served as an Executive Vice President, Operations & Chief Operations Officer at Alexza Pharmaceuticals where he had operational oversight, including the scale-up and optimization of supply that supported the launch of the company’s first commercial product, and advancement of a platform proof-of-concept that enabled acceleration of the company’s product pipeline. Before joining Alexza, Mr. Lippe served as the Head of Global Operations & Operational Excellence at Ironwood Pharmaceuticals, Inc., where he was responsible for building and leading the company’s worldwide operations division. Prior to Ironwood Pharmaceuticals, Mr. Lippe worked for Genentech, Inc. where he served as the Head of Manufacturing for Genentech's Vacaville Operations after holding multiple positions in strategic operations, drug substance and product manufacturing, and facilities management. Previously, Mr. Lippe spent ten years at Lawrence Livermore National Laboratory and six years as an officer in the U.S. Coast Guard. Mr. Lippe received his MPH and MBA degrees from the University of California, Berkeley, and received a BS degree in marine engineering from the United States Coast Guard Academy.

Frank J. Malinoski, M.D., Ph.D., Chief Medical Officer
Dr. Malinoski has more than 20 years of executive experience in the biotech and pharmaceutical industries, including work in clinical and global business development, regulatory evaluation, and post-approval oversight for numerous vaccines and immunotherapy products. Dr. Malinoski has extensive background in the fields of vaccines, immunology, oncology, infectious disease and other key therapeutic areas. Prior to joining Liquidia in 2010, Dr. Malinoski held senior positions in clinical research, business development, and medical affairs at Wyeth, MedImmune, Nabi and several other biopharmaceutical companies. His responsibilities included pre-licensure clinical evaluation and post-licensure activities in support of vaccines and immunotherapy, and his efforts contributed to the licensure of Prevnar, Meningitec, and Tetramune vaccines. Dr. Malinoski received his B.A. from Colby College, his M.D. from Albany Medical College, and his Ph.D. in microbiology from Rutgers University.

Ash Nijhawan, Vice President, Business Development
Mr. Nijhawan joined Liquidia in 2010 from Schering-Plough, Corp. where he was responsible for all aspects of merger & acquisition, licensing, & divestiture transactions. Prior to joining Schering Plough, he was a Director in Pfizer's Management Science Group where he worked closely with a team to identify, evaluate, and support the negotiation of in-license drug candidates. Prior to joining Pfizer, Mr. Nijhawan spent two years at Stern Stewart & Company and started his career at General Electric Company. Mr. Nijhawan has a M.B.A. from New York University and a B.S. in Electrical Engineering from North Carolina State University.


 

© 2015 Liquidia Technologies | PO Box 110085 | Research Triangle Park, NC 27709 | P.919.328.4400 | F.919.328.4402 | email: info@liquidia.com